OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly making false and misleading statements regarding its capital allocation priorities and dividend payouts, leading to significant investor losses [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to violations of the Securities Exchange Act of 1934, specifically §§10(b) and 20(a), and Rule 10b-5 [1]. - Investors who purchased Organon's securities between October 31, 2024, and April 30, 2025, are encouraged to participate in the lawsuit before the deadline of July 22, 2025 [2]. - The class has not yet been certified, meaning potential participants are not currently represented by an attorney [3]. Group 2: Allegations Against Organon - The complaint alleges that Organon concealed important information about its capital allocation priorities, particularly regarding its quarterly dividend payout [4]. - The company had previously reported that maintaining quarterly dividends was its "number one priority," which contradicted its debt reduction strategy, ultimately resulting in a 70% reduction in dividends [4]. - The misleading public statements made by Organon throughout the class period led to investor damages once the truth was revealed [4].